Volume 40, Issue 3, 2022-7-1, Pages i-337

Articles in this issue:

1. Food and Drug Administration’s Role in Dermatology

2. Copyright

3. Contributors

4. Contents

5. Forthcoming Issues

6. Food and Drug Administration’s Role in Dermatology

7. The US Food and Drug Administration’s Intersection with Dermatology

8. The History of Dermatology and Dermatologists at the US Food and Drug Administration

9. The Food and Drug Administration’s Role in Dermatologic Drug Development

10. Postmarket Assessment for Drugs and Biologics Used in Dermatology and Cutaneous Adverse Drug Reactions

11. How Does the Food and Drug Administration Approve Topical Generic Drugs Applied to the Skin?

12. Dermatology Drugs for Children—U.S. Food and Drug Administration Perspective

13. Regulation of Medical Devices for Dermatology

14. Regulation of Cosmetics in the United States

15. Cutaneous Pharmacokinetic Approaches to Compare Bioavailability and/or Bioequivalence for Topical Drug Products

16. Measuring What Matters to Patients in Dermatology Drug Development